drugset / Trial / NCT05241093
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
NaSequentialOpen-labelTreatment
Summary
This is a single-arm, open, multicenter, phase 2 study to evaluate the efficacy, safety and pharmacokinetics of HYLM-122 in combination with cytarabine in Chinese subjects with FLT3 positive relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2022-03-29
- Primary completion
- 2025-12-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HYML-122 | Unknown | 400 mg | Oral |
| Subject | HYML-122 | Unknown | 600 mg | Oral |
| Background | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |